Nephro Care India IPO (SME) Overview

Nephro Care India Limited located in Kolkata, offers a wide range of clinical and lifestyle solutions, as well as renal insufficiency treatment for patients. Nephro Care India IPO to raise ₹41.26 Cr comprises fresh issue of 45.84 lakh equity Shares with a face value of Rs 10 each in the price band of Rs 85 – Rs 90 per share.

IPO opensJune 28, 2024
IPO ClosesJuly 2 2024
IPO Size (Rs.)₹41.26 Cr
IPO Size (shares)6,432,000 shares
BreakupFresh issue only
Face Value:₹ 10
IPO Price in Rs :₹85 to ₹90 per share
Minimum Lot1600 Shares
Listing AtNSE SME
QIB~50 %
NII Quota~15%
Retail Quota~35%
 Lead ManagerCorporate Capitalventures Pvt Ltd
Registrar Bigshare Services Pvt Ltd 
Market maker Ss Corporate Securities.


Nephro Care India IPO: Short Notes

  • Nephro Care was founded inr 2021 by Dr. Pratim Sengupta, in Kolkata, one of the leading nephrologists in India,
  • They are a comprehensive treatment center located in Kolkata, offering a wide range of clinical and lifestyle solutions, as well as renal insufficiency treatment for patients.
  • Dr. Sengupta, has performed more than 1,000 kidney transplants till now and combines holistic renal care tof clinical intervention, yoga and lifestyle support.
  • As of the date of this offer document, they had 127 employees on their payroll. 
  • Nephro Care intends to use Rs 26.17 crore for setting-up a multi-specialty healthcare facility in Kolkata.
  • The new hospital will have 100 inpatient beds, including a 30-bed Critical Care unit . It will offer treatment services in areas like cardiology, medical oncology, gastroenterology, gynaecology including an advanced renal transplant unit.
  • Nephro Care India IPO raised Rs 11.14 crore from anchor investors including CCV Emerging Opportunities Fund – I, Persistent Growth Fund – Varsu India Growth Story Scheme 1 and Vikasa India EIF I Fund – Incube Global Opportunities.
  • For the 9mFY24 it earned a net profit of Rs. 3.4 cr. on income of Rs. 19.9 cr.
  • Based on annualized FY24 earnings Nephro Care India IPO is at a P/E of 32.73.
  • Management has indicated better results in FY25 as more units come on stream.
  • I intend to apply in Nephro Care India IPO. In my view company should do well.
  • Due to current market conditions and being only issue open now, more than 1o00x subscription is expected.
  • GMP as reported on social media has been Rs. 155 (172%)
  • Corporate Capitalventure is the Lead Manager with a good record. Past issues handled by them include GP Eco Solutions India Limited, Creative Graphics Solutions India Limited, Trust Fintech Limited, Esconet Technologies, Alpex Solar Limited, Accent Microcell Limited, Rockingdeals Circular Economy, Oriana Power Limite, Crayons Advertising Limited, Droneacharya Aerial Innovations Limited, Annapurna Swadisht Limited, Rajnandini Metal Limited, Swastik Pipe Limited, Uma Exports Limited, Phantom Digital Effects Limited, Nupur Recyclers etc.
  • SME IPOs are quite volatile and new retail investors need to exercise considerable caution in my view.
  • This post is exploratory and educational purposes only. Please do your own diligence before investing in SME IPOs like this.
  • Standard disclaimer: I am not a SEBI registered analyst and above analysis is for educational purpose only. Iam a postgraduate in engineering & Management . I have in the past cleared some exams like NISM-Series-V-A: Mutual Fund Distributors Certification, NISM-Series-X-A: Investment Adviser (Level 1) Certification and NISM-Series-X-B: Investment Adviser (Level 2) Examination. This post is my view on the subject matter and is only academic and exploratory in nature. It is not meant to influence investment decisions of investors. I may have bias/vested interest in covered Stock/Mutual Funds/NCD etc. due to my own investment or leaning. Further my understanding of the areas on which I write may be imperfect or incomplete and data could be wrong due to limited time and resources at my disposal. Do check the data from company’s RHP and exchanges before making any decision. Please do your own due diligence as stock market/MF investments have high degree of inherent risk.

Leave a Reply